Trius Therapeutics
6310 Nancy Ridge Drive
Suite 105
San Diego
California
92121
United States
Tel: 858-452-0370
Fax: 858-452-0412
Website: http://www.triusrx.com/
Email: info@triusrx.com
94 articles about Trius Therapeutics
-
Mainstay Medical Announces the Appointment of Matthew Onaitis as Chief Financial Officer
8/20/2018
Mainstay Medical International plc (“Mainstay” or the “Company”, Euronext Paris: MSTY.PA and Euronext Dublin: MSTY.IE), a medical device company focused on bringing to market ReActiv8®, an implantable restorative neurostimulation system to treat disabling Chronic Low Back Pain, announces the appointment of Matthew Onaitis as Chief Financial Officer, effective August 20, 2018.
-
Cubist Pharmaceuticals, Inc. Completes Acquisition of Trius Therapeutics
9/12/2013
-
Cubist Pharmaceuticals, Inc. Announces Results of Tender Offer for Outstanding Shares of Trius Therapeutics
9/11/2013
-
Cubist Pharmaceuticals, Inc. Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of Trius Therapeutics
8/30/2013
-
Cubist Pharmaceuticals, Inc. Commences Tender Offer for All Outstanding Shares of Trius Therapeutics
8/14/2013
-
Trius Therapeutics Reports Second Quarter 2013 Financial Results
8/7/2013
-
Trius Therapeutics to Present at the JMP Securities Healthcare Conference
7/8/2013
-
Trius Therapeutics Announces Publication of Antibiotic Safety Study in Antimicrobial Agents and Chemotherapy
6/12/2013
-
Trius Therapeutics Appoints Matthew Onaitis as General Counsel
6/3/2013
-
Trius Therapeutics Announces Notice of Allowance of U.S. Patent Application Related to Tedizolid Phosphate Combination With Daptomycin
5/13/2013
-
Trius Therapeutics to Present Experimental Antibiotic Study Results at ECCMID Meeting
4/23/2013
-
Trius Therapeutics's Tedizolid Meets Endpoint in Ph3
3/25/2013
-
Trius Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares for Common Stock Offering
1/23/2013
-
Trius Therapeutics Prices Public Offering of Common Stock
1/18/2013
-
Trius Therapeutics Completes Enrollment in Second Phase 3 Trial of Tedizolid for Skin and Skin Structure Infections
12/10/2012
-
Trius Therapeutics Ranked Number 42 Fastest Growing Company in North America on Deloitte & Touche LLP (New York, New York)'s 2012 Technology Fast 500
11/15/2012
-
Trius Therapeutics to Present at November Investor Conferences
11/12/2012
-
Trius Therapeutics to Host Analyst and Investor Update Call
11/9/2012
-
Trius Therapeutics Reports 2012 Third Quarter Financial Results
11/6/2012
-
Trius Therapeutics Release: Tedizolid Safety Data Presented at IDWeek
10/22/2012